Objective:To investigate the effects of atorvastatin combined with trimetazidine on heart function, oxidative stress and inflammatory factors in patients with coronary heart disease, Methods:110 patients with coronary...Objective:To investigate the effects of atorvastatin combined with trimetazidine on heart function, oxidative stress and inflammatory factors in patients with coronary heart disease, Methods:110 patients with coronary heart disease from June 2015 to June 2016 in our hospital were selected as the research objects, randomly divided into observation group 55 cases and control group 55 cases, The patients in both groups received conventional treatment of coronary heart disease, and the control group was given orally atorvastatin calcium capsules at the same time. The observation group was added with trimetazidine hydrochloride tablets on the basis of the control group. The left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end-diastolic diameter (LVESD), C reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), superoxide dismutase (SOD) and MDA levels of two groups were compared respectively before and after treatment. Results: Before treatment, the LVESD, LVEDD and LVEF levels between observation group and the control group had no significant difference (P>0.05);Compared with before treatment, LVESD and LVEDD levels in the observation group and control group after treatment were significantly decreased, LVEF increased significantly, and there were significant differences (P<0.05);After treatment, the observation group LVESD and LVEDD were lower than the control group, LVEF in the observation group after treatment was higher than the control group, and the differences were statistically significant (P<0.05). Before treatment, SOD and MDA between the observation group and the control group had no significant difference (P>0.05);After treatment, SOD in the observation group and the control group were significantly increased, MDA decreased significantly, and the differences were statistically significant (P<0.05);After treatment, SOD in the observation group was higher than the control group, MDA in the observation group was lower than the control group, and the differences were statistically significant (P<0.05). Before treatment, CRP, TNF-α, and IL-6 between the observation group and the control group had no significant difference (P>0.05);compared with before treatment, the CRP, TNF-α, and IL-6 of observation group and control group after treatment were significantly decreased, and the differences were statistically significant (P<0.05);After treatment, CRP, TNF-α, and IL-6 of the observation group were lower than the control group, and the difference was statistically significant (P<0.05).Conclusions:Atorvastatin combined with trimetazidine can more significantly improve cardiac function in patients with coronary heart disease, reduce oxidative stress and inflammation.展开更多
文摘Objective:To investigate the effects of atorvastatin combined with trimetazidine on heart function, oxidative stress and inflammatory factors in patients with coronary heart disease, Methods:110 patients with coronary heart disease from June 2015 to June 2016 in our hospital were selected as the research objects, randomly divided into observation group 55 cases and control group 55 cases, The patients in both groups received conventional treatment of coronary heart disease, and the control group was given orally atorvastatin calcium capsules at the same time. The observation group was added with trimetazidine hydrochloride tablets on the basis of the control group. The left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end-diastolic diameter (LVESD), C reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), superoxide dismutase (SOD) and MDA levels of two groups were compared respectively before and after treatment. Results: Before treatment, the LVESD, LVEDD and LVEF levels between observation group and the control group had no significant difference (P>0.05);Compared with before treatment, LVESD and LVEDD levels in the observation group and control group after treatment were significantly decreased, LVEF increased significantly, and there were significant differences (P<0.05);After treatment, the observation group LVESD and LVEDD were lower than the control group, LVEF in the observation group after treatment was higher than the control group, and the differences were statistically significant (P<0.05). Before treatment, SOD and MDA between the observation group and the control group had no significant difference (P>0.05);After treatment, SOD in the observation group and the control group were significantly increased, MDA decreased significantly, and the differences were statistically significant (P<0.05);After treatment, SOD in the observation group was higher than the control group, MDA in the observation group was lower than the control group, and the differences were statistically significant (P<0.05). Before treatment, CRP, TNF-α, and IL-6 between the observation group and the control group had no significant difference (P>0.05);compared with before treatment, the CRP, TNF-α, and IL-6 of observation group and control group after treatment were significantly decreased, and the differences were statistically significant (P<0.05);After treatment, CRP, TNF-α, and IL-6 of the observation group were lower than the control group, and the difference was statistically significant (P<0.05).Conclusions:Atorvastatin combined with trimetazidine can more significantly improve cardiac function in patients with coronary heart disease, reduce oxidative stress and inflammation.
